Full Press Release Details
Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene
Subsidiary offers 100 select recombinant proteins in its BioReagents
ALAMEDA, Calif.--(BUSINESS WIRE)--April 10, 2013--LifeMap Sciences,
Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today
that it is now offering 100 selected ProSpec-Tany TechnoGene (ProSpec)
manufactured recombinant proteins related to stem cell research in its
recently launched LifeMap BioReagents portal (http://bioreagents.lifemapsc.com)
to researchers worldwide. ProSpec's innovative recombinant proteins,
including growth factors, signaling molecules, differentiation factors,
hormones, cytokines and chemokines will complement the current BioTime
research product lines available via LifeMap BioReagents ,
including BioTime's PureStem human progenitor cell lines, PureStem
packages, clinical and research grade human embryonic stem cell lines
(hES), ESpan growth media for progenitor cell lines, and cell
differentiation media.
The addition of ProSpec products reflects LifeMap Sciences'
execution of its strategy to market a growing catalog of research
products to aid scientists in a variety of fields, including stem cell
research, developmental biology, mechanisms of various human diseases
and drug and therapeutic discovery.
LifeMap Sciences holds an exclusive, worldwide license to market GeneCards
(www.genecards.org), the human gene compendium, and MalaCards
(www.malacards.org), a database with nearly 17,000 human
disease entries, from Yeda Research and Development Company Ltd., the
commercial arm of the Weizmann Institute of Science. Additionally, it
has recently launched version 1.1 of LifeMap Discovery , a
comprehensive embryonic development and stem cell compendium, a database
owned and developed by LifeMap Sciences. According to Google Analytics,
the sites have generated more than 2,000,000 unique visitors with more
than 13,000,000 page views in the past 12 months. Links from LifeMap
Discovery to BioTime and ProSpec manufactured products in the LifeMap
BioReagents portal will enable researchers who access the
database to become familiar with, and purchase, products that relate
directly to the types of cells, genes or diseases that they are studying
and can assist them in various research projects.
"We are pleased to meet this significant milestone in our e-Commerce
strategy," stated Yaron Guan-Golan, Head of Marketing at LifeMap
Sciences. "Our growing LifeMap Discovery user base will now be able to
identify high quality recombinant proteins that can be helpful for their
research and purchase them via LifeMap BioReagents . This will
increase LifeMap BioReagents brand awareness and the quality of
our offering to the global biomedical research community."
About LifeMap Sciences, Inc.
LifeMap Sciences' (www.lifemapsc.com) core technology and
business is based on its integrated database suite, the discovery
platform for biomedical and stem cell research. This platform includes GeneCards ,
the leading human gene database; LifeMap Discovery , the database
of embryonic development, stem cell research and regenerative medicine;
and MalaCards, the human disease database. LifeMap Sciences also
markets PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.
In addition to database offerings, LifeMap Sciences is BioTime's
principal marketing subsidiary for research products, including PureStem
human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan
growth media for progenitor cell lines, and cell differentiation media
for non-therapeutic uses, via its LifeMap BioReagents portal.
LifeMap Sciences utilizes its databases as part of its online marketing
strategy to reach life sciences researchers at biotech and
pharmaceutical companies and at academic institutions and research
hospitals worldwide.
In a therapeutic discovery collaboration with BioTime, LifeMap's
scientists utilize LifeMap's proprietary platform, including LifeMap
Discovery , its stem cell database along with the GeneCards
and MalaCards integrated database suite, to aid in the
development of BioTime's proprietary PureStem human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell
replacement therapies. The LifeMap Discovery platform will be
used to select the progenitor cell lines that are most likely to be
useful in developing cell-based regenerative medicine therapies for a
wide range of diseases.
About ProSpec-Tany TechnoGene Ltd.
ProSpec (Protein-Specialists) is a leading biotechnology company having
over 19 years of experience specializing in production of
bacterial-derived recombinant proteins. ProSpec produces a wide array of
Cytokines, Growth Factors, Chemokines, Hormones, Enzymes, Viral Antigens
and many other recombinant proteins.
ProSpec's proprietary protein purification technologies with over a
decade of extensive experience result in low production costs, high
yield, production efficiency, utmost pure products and uncompromising
biological activity at competitive prices. ProSpec provides custom
in-house production services of recombinant proteins tailored to the
ProSpec provides proteins, services and technology license to a broad
range of customers around the globe from academic and government
research institutions, biotechnology and pharmaceutical companies, as
well as hospitals and reference laboratories.
ProSpec's goal is to supply proteins which are crucial to the research
industry to meet and exceed quality, consistency and requirements by our
customers worldwide. The company welcomes partnerships with
pharmaceutical and industrial companies for development of future
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of application. BioTime
develops and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem
cell lines, HyStem hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia (formerly
known as HyStem -Rx), a biocompatible,